Authors: Ashok Chakraborty, Anil Diwan.
A recent clinical trial (Clinical Trial: NCT04315948) by Florence Ader et al., published on the preprint server medRxiv (Posted April 12, 2022), reported that RDV was not associated with clinical improvement at day 15 or day 29, nor with a reduction in mortality, nor with a reduction in SARS-CoV-2 RNA. In cell culture studies with SARS-CoV-2 infection in a variety of cell types, the antiviral effect of RDV was satisfactory. However, the authors of this clinical trial state that the efficacy of the drug and its toxicity in humans is over predicted. However, we came up with our own evaluation from our most relevant experimental results.
View/Download pdf